Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Rhea-AI Summary
Castle Biosciences (Nasdaq:CSTL) announced that chief financial officer Frank Stokes was named a 2026 CFO Awards honoree by the Houston Business Journal. He is one of 22 CFOs recognized in Greater Houston for financial leadership and organizational impact.
Stokes has served as CFO since December 2017, helping guide Castle Biosciences’ 2019 Nasdaq IPO and supporting growth through multiple strategic acquisitions. Honorees will be celebrated July 30 and featured in the July 31 print and digital issues.
Positive
- None.
Negative
- None.
News Market Reaction – CSTL
In the Jun 23 session, CSTL gained 0.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 16 | Product adoption milestone | Positive | -1.0% | TissueCypher test surpassing 100,000 clinical orders milestone announcement. |
| May 13 | Conference participation | Positive | -2.6% | Jefferies Global Healthcare Conference presentation and webcast details. |
| May 12 | Industry award win | Positive | -2.1% | AdvanceAD-Tx test receiving MedTech Breakthrough Genomics Innovation Award. |
| May 06 | Earnings and guidance | Positive | -22.3% | Q1 2026 results with raised full-year revenue guidance and growth metrics. |
| May 05 | Advocacy initiatives | Positive | -3.6% | Support for nationwide advocacy and screening during Skin Cancer Awareness Month. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
CSTL has often traded lower following generally positive corporate and operational news over the past six months.
Key Terms
initial public offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Stokes was one of 22 financial leaders recognized in the
Stokes is among 22 chief financial officers from across the
"Frank exemplifies the combination of financial discipline and strategic vision that has allowed Castle Biosciences to grow and serve patients," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Frank has served as Castle's chief financial officer since December 2017, helping lead the company through its successful Nasdaq initial public offering in 2019 and supporting its growth through multiple strategic acquisitions."
"It is an honor to be recognized among so many outstanding financial leaders in
Stokes has twice been named a Top 25 CFO of
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-chief-financial-officer-frank-stokes-named-a-2026-cfo-awards-honoree-by-the-houston-business-journal-302807013.html
SOURCE Castle Biosciences, Inc.